{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:17:40Z","timestamp":1787771860599,"version":"build-2784847793"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vaccines, including COVID-19 vaccines, are known to be cost-effective interventions for disease prevention and control. However, adverse events following immunisation (AEFI) may challenge the acceptance of these vaccines. This study assessed the prevalence and severity of COVID-19-related AEFI amongst healthcare workers at tertiary health facilities in Nigeria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This descriptive, cross-sectional study was conducted among healthcare workers who had received the COVID-19 vaccine. A multi-stage sampling technique was used to select participants from six Tertiary Health Facilities in Nigeria. Ethical approval (NHREC\/01\/01\/2007-19\/07\/2021) was obtained from NHREC. Data were analysed using IBM\u00ae SPSS version 25 and categorical variables were presented in tables\/charts using frequencies and proportions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 2130 respondents participated in the study, with a mean age of 37.4 \u00b1 9.1 years. Most of the respondents, 1674 (78.6%), had two doses of the vaccine, and the overall prevalence of AEFI was 813 (38.2%). Common among the AEFI reported following the administration of the first dose of the vaccine were fever 649 (30.5%) and pain at the injection site 644 (30.2%), while it was pain at the injection site 216 (10.1%) and fever 173 (8.1%) for second dose. The higher proportions of AEFI were mostly mild to moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The study observed a relatively low prevalence of AEFI, with the commonly reported ones being fever and injection site pain. It is crucial that countries continuously collect the data on AEFI and establish causality as a way to improve quality and guarantee vaccine safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/npmj.npmj_227_23","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T02:01:29Z","timestamp":1707271289000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Vaccine Safety: Assessing the Prevalence and Severity of Adverse Events Following COVID-19 Vaccination amongst Healthcare Workers in Tertiary Health Facilities in Nigeria"],"prefix":"10.4103","volume":"31","author":[{"given":"Ayotunde Sherif","family":"Azees","sequence":"first","affiliation":[{"name":"Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojirola Martina","family":"Fasiku","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulfattah","family":"Isa","sequence":"additional","affiliation":[{"name":"Department of Public Health, Federal Medical Centre, Birnin Kebbi, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuna Zainab","family":"Ezenwoko","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Usmanu Danfodiyo University Teaching Hospital, Argungu, Kebbi State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullahi","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola Oluwatoyin","family":"Temitayo-Oboh","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowland","family":"Utulu","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makinde Adebayo","family":"Adeniyi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar","family":"Musa","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihurumnanya","family":"Alo","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman Muhammed","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Federal University Dutse, Dutse, Jigawa State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Bosede","family":"Imhonopi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseun Opeyemi","family":"Adesoye","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Medicine Delta State University Teaching Hospital, Oghara, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeyinwa Maureen","family":"Okeke","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godwin ThankGod","family":"John","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulquadri Yeketi","family":"Ayinla","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"R1-20240908","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41256-020-00135-6","article-title":"The novel coronavirus outbreak in Wuhan, China","volume":"5","author":"Zhu","year":"2020","journal-title":"Glob Health Res Policy"},{"key":"R2-20240908","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijid.2020.06.067","article-title":"Coronavirus outbreak in Nigeria:Burden and socio-medical response during the first 100 days","volume":"98","author":"Amzat","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R3-20240908","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"key":"R4-20240908","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12889-021-10351-5","article-title":"Impacts of the COVID-19 lockdown and relevant vulnerabilities on capability well-being, mental health and social support:An Austrian survey study","volume":"21","author":"Simon","year":"2021","journal-title":"BMC Public Health"},{"key":"R5-20240908","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent Sci"},{"key":"R6-20240908","first-page":"315","article-title":"The concept analysis of body image of people living with HIV\/AIDS","volume":"7","author":"Yang","year":"2015","journal-title":"Int J BioSci BioTechnol"},{"key":"R7-20240908","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/acsptsci.9b00032","article-title":"The HPV vaccine story","volume":"2","author":"Frazer","year":"2019","journal-title":"ACS Pharmacol Transl Sci"},{"key":"R8-20240908","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1093\/infdis\/jiaa598","article-title":"The rotavirus vaccine story:From discovery to the eventual control of rotavirus disease","volume":"224","author":"Glass","year":"2021","journal-title":"J Infect Dis"},{"key":"R9-20240908","doi-asserted-by":"crossref","first-page":"e0266724","DOI":"10.1371\/journal.pone.0266724","article-title":"Assessment of COVID-19 vaccine hesitancy among Zimbabweans:A rapid national survey","volume":"17","author":"Mundagowa","year":"2022","journal-title":"PLoS One"},{"key":"R10-20240908","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41182-021-00393-1","article-title":"Hesitancy in COVID-19 vaccine uptake and its associated factors among the general adult population:A cross-sectional study in six Southeast Asian countries","volume":"50","author":"Marzo","year":"2022","journal-title":"Trop Med Health"},{"key":"R11-20240908","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s41256-022-00255-1","article-title":"COVID-19 vaccine hesitancy in Africa:A scoping review","volume":"7","author":"Ackah","year":"2022","journal-title":"Glob Health Res Policy"},{"key":"R14-20240908","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK:A prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R15-20240908","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jcm10071428","article-title":"Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic","volume":"10","author":"Riad","year":"2021","journal-title":"J Clin Med"},{"key":"R16-20240908","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40615-015-0101-3","article-title":"Racial and ethnic disparities in adverse drug events:A systematic review of the literature","volume":"2","author":"Baehr","year":"2015","journal-title":"J Racial Ethn Health Disparities"},{"key":"R17-20240908","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1016\/j.vaccine.2022.04.054","article-title":"Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants:A report of interim findings","volume":"40","author":"Iwata","year":"2022","journal-title":"Vaccine"},{"key":"R18-20240908","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"R19-20240908","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV:A randomized, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R20-20240908","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years:A randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R21-20240908","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152:Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R24-20240908","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.it.2015.06.005","article-title":"Utilizing population variation, vaccination, and systems biology to study human immunology","volume":"36","author":"Tsang","year":"2015","journal-title":"Trends Immunol"},{"key":"R25-20240908","doi-asserted-by":"crossref","first-page":"e00084","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"R26-20240908","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13690-021-00741-x","article-title":"Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021","volume":"79","author":"Konu","year":"2021","journal-title":"Arch Public Health"},{"key":"R27-20240908","first-page":"637","article-title":"Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination","volume":"77","author":"Rahmat","year":"2022","journal-title":"Med J Malaysia"},{"key":"R28-20240908","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40264-022-01151-w","article-title":"Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands","volume":"45","author":"Kant","year":"2022","journal-title":"Drug Saf"},{"key":"R29-20240908","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/vaccines9101090","article-title":"Aretrospective Cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh","volume":"9","author":"Sultana","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"R30-20240908","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/vaccines9101096","article-title":"Adverse events following immunization associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea","volume":"9","author":"Jeon","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"R31-20240908","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40360-021-00528-4","article-title":"COVID-19 vaccines programs:Adverse events following immunization (AEFI) among medical clerkship student in Jember, Indonesia","volume":"22","author":"Supangat","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"R32-20240908","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1542\/peds.2006-0678","article-title":"Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine","volume":"118","author":"LeBaron","year":"2006","journal-title":"Pediatrics"},{"key":"R33-20240908","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12865-017-0226-8","article-title":"Adverse events following immunization with pentavalent vaccine:Experiences of newly introduced vaccine in Iran","volume":"18","author":"Karami","year":"2017","journal-title":"BMC Immunol"},{"key":"R34-20240908","first-page":"23","article-title":"Adverse events following immunization against COVID-19 among healthcare workers:An observational study in Haryana, India","volume":"13","author":"Chaudhary","year":"2022","journal-title":"India Asian J Med"},{"key":"R35-20240908","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/j.mjafi.2021.06.014","article-title":"Adverse events following ChAdOx1 nCoV-19 vaccine (COVISHIELD) amongst health care workers:A prospective observational study","volume":"77","author":"Kamal","year":"2021","journal-title":"Med J Armed Forces India"},{"issue":"Suppl 4","key":"R36-20240908","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1093\/cid\/ciu611","article-title":"Evaluating associations between vaccine response and malnutrition, gut function, and enteric infections in the MAL-ED cohort study:Methods and challenges","volume":"59","author":"Hoest","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R37-20240908","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the elderly:The challenge of immune changes with aging","volume":"40","author":"Ciabattini","year":"2018","journal-title":"Semin Immunol"},{"key":"R38-20240908","doi-asserted-by":"crossref","first-page":"870599","DOI":"10.3389\/fphar.2022.870599","article-title":"Profiling COVID-19 vaccine adverse events by statistical and ontological analysis of VAERS case reports","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"key":"R39-20240908","doi-asserted-by":"crossref","first-page":"e0272729","DOI":"10.1371\/journal.pone.0272729","article-title":"Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine:A comparative study among healthcare professionals of Nepal","volume":"17","author":"Rayamajhi","year":"2022","journal-title":"PLoS One"},{"key":"R40-20240908","doi-asserted-by":"crossref","first-page":"2109365","DOI":"10.1080\/21645515.2022.2109365","article-title":"Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines:A descriptive analysis from VigiAccess","volume":"18","author":"Yamoah","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"R41-20240908","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12879-022-07411-5","article-title":"Adverse effects following COVID-19 vaccination in Iran","volume":"22","author":"Babaee","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R42-20240908","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/422454","article-title":"Fever after immunization:Current concepts and improved future scientific understanding","volume":"39","author":"Kohl","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R43-20240908","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1186\/s12889-021-11387-3","article-title":"The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018","volume":"21","author":"Hu","year":"2021","journal-title":"BMC Public Health"},{"key":"R44-20240908","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/vaccines10060924","article-title":"Surveillance of post-vaccination side effects of COVID-19 vaccines among Saudi population:A real-world estimation of safety profile","volume":"10","author":"Alzarea","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R45-20240908","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children:Two open-label, randomised controlled trials","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"},{"key":"R46-20240908","doi-asserted-by":"crossref","first-page":"e12223","DOI":"10.2196\/12223","article-title":"Postvaccination fever response rates in children derived using the fever coach mobile app:A retrospective observational study","volume":"7","author":"Ahn","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"R47-20240908","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2:A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"R48-20240908","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1016\/j.vaccine.2021.09.060","article-title":"Factors influencing adverse events following immunization with AZD1222 in vietnamese adults during first half of 2021","volume":"39","author":"Tran","year":"2021","journal-title":"Vaccine"}],"container-title":["Nigerian Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_227_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:18:25Z","timestamp":1787768305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_227_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/npmj.npmj_227_23","relation":{},"ISSN":["1117-1936","2468-6875"],"issn-type":[{"value":"1117-1936","type":"print"},{"value":"2468-6875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-09-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}